Orion Market Research (OMR)
recently published a market research report on the global Myocardial
Infarction Treatment market. According to OMR
analysis, the global myocardial infarction treatment market is estimated to grow at a
significant CAGR during the forecast period (2018-2023). The crucial factors
contributing to the growth of the global myocardial infarction treatment market
include rising incidence rate of CVD (cardiovascular disease) and intake of
high-level sugary food, which significantly increased
the prevalence of CADs (coronary artery diseases). Moreover, the shift towards
sedentary lifestyle and faulty dietary habits coupled with lack of physical
activity are some other factors fueling the growth of the market. However, the high cost of myocardial infarction treatment
and delay in certification and approval for heart treatment are some factors
restraining the growth of the market.
A full report of global myocardial infarction
treatment market is available at
Furthermore, the global myocardial
infarction treatment market is segmented on the basis of type, device,
diagnosis, treatment and end-users. The report provides detailed &
insightful chapters which include market overview, key findings, strategic
recommendations, market estimations, market determinants, key company analysis,
market insights, company profiling, market segmentation, geographical analysis,
analyst insights and predictive analysis of the market.
Market Segmentation
1.
Global Myocardial
Infarction Treatment Market by Type
·
ST-Segment Elevation Myocardial Infarction (STEMI) Heart Attacks
·
Non-ST Segment Elevation
Myocardial Infarction (NSTEMI) Heart Attacks
·
Silent Heart Attacks
2.
Global Myocardial
Infarction Treatment Market by Device
·
Left Ventricular Assist
Device
·
Pacemaker
·
Implantable Cardioverter
Defibrillator
·
Others (Aspiration-Based
Catheters)
3.
Global Myocardial
Infarction Treatment Market by Diagnosis
·
Electrocardiography (ECG)
·
Chest X-Ray
·
Computed Tomography (CT
Scan)
·
Echocardiography
·
Others (Blood Test)
4.
Global Myocardial
Infarction Treatment Market by Treatment
·
Medication
o Analgesics
o Thrombolytic
o Antiplatelet Agents
o Glycoprotein IIb/IIIa Inhibitors
o Others (Adrenergic Blockers)
·
Surgery
o Angioplasty
o Bypass Surgery
o Heart Transplant
5.
Global Myocardial
Infarction Treatment Market by End-Users
·
Hospital & Clinics
·
Ambulatory Surgical
Centers
·
Research Institutes
Regions Covered
•
North America (the US and Canada)
•
Europe (UK, Germany,
France, Spain, and Italy)
•
Asia-Pacific (China,
India, South Korea, and Japan)
•
Rest of the World (Middle East & Africa and Latin America)
Company Profiles
·
advanceCOR GmbH
·
Anthera Pharmaceuticals, Inc.
·
AstraZeneca PLC
·
Athersys, Inc.
·
Bayer AG
·
BioVascular, Inc.
·
Boehringer Ingelheim International GmbH
·
BRISTOL-MYERS SQUIBB Co.
·
Caladrius Biosciences, Inc.
·
Capricor Therapeutics, Inc.
·
CSL Behring
·
GlaxoSmithKline PLC
·
GNT Pharma Co., Ltd
·
Johnson & Johnson
·
Merck KGaA
·
Mesoblast Ltd.
·
Mylan N.V.
·
NeuroVive Pharmaceutical AB
·
Novartis International AG
The key objectives of the Myocardial Infarction Treatment study:
·
To analyze the Myocardial
Infarction Treatment Market size (values and volume) by segments with
historical data of 2017 and 2018 and forecast to 2025.
·
To study the key factors influencing the growth
of the market.
·
Focuses on the key leaders to define and analyze
the sales volume, value, share, competitive landscapes, SWOT analysis, and
development plans.
·
To analyze the Myocardial
Infarction Treatment Market growth, global trends, future prospectus and
contribution to the market.
Related Reports:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404
No comments:
Post a Comment